Calidi Biotherapeutics Inc. (CLDI) Soars 57.61% on Cancer Treatment Advances

On July 9, 2025, Calidi Biotherapeutics Inc. (NYSE American: CLDI) experienced a remarkable surge, with its stock price rising by 57.61% in pre-market trading. This significant increase reflects growing investor confidence in the company's innovative approach to cancer treatment.

Calidi Biotherapeutics has been actively engaged in developing a precision genetic medicine platform aimed at revolutionizing cancer treatment. The company's recent announcements, including the placement in an editorial by NetworkNewsWire and a shareholder letter from the CEO, have highlighted its advancements in systemic oncolytic targeted therapies. These developments have garnered attention from investors, contributing to the stock's recent surge.

Additionally, Calidi Biotherapeutics has made strides in its clinical trials, announcing the commencement of recruitment for a multiple-dose CLD-101 trial in patients with newly diagnosed high-grade glioma at Northwestern University Hospital. This trial is a crucial step in validating the company's innovative therapies and could pave the way for broader clinical applications.

Furthermore, the company's financial maneuvers, such as the closing of a $3.9 million registered direct offering and concurrent private placement, have bolstered its cash balance. This financial stability allows Calidi to continue its research and development efforts, further enhancing its position in the biotechnology sector.